Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma.

P921

Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma.

Item

http://www.wikidata.org/entity/Q38621223

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Society for Immunotherapy of C ...... reatment of bladder carcinoma.

@en

type

Item

label

Society for Immunotherapy of C ...... reatment of bladder carcinoma.

@en

prefLabel

Society for Immunotherapy of C ...... reatment of bladder carcinoma.

@en

P1433

Q38621223-26D06C57-DAE3-45BE-B079-85F7B69F8B5B

P1476

Q38621223-1875AD99-1C0C-40F3-9D48-81C19727CB2C

P2093

Q38621223-15F5D651-48A9-45F5-95AA-B66993517C8B

Q38621223-1E1823EB-B47D-409C-A872-43C1903C18C8

Q38621223-34FA8CB2-8BE3-4BED-9CBD-98E95DF99050

Q38621223-4769D3D5-235E-4631-811C-4A1DDC608D2B

Q38621223-4DE4E2A1-A925-4490-A102-11A909DB9336

Q38621223-5353E02C-6098-4D56-A8F0-B8BCADDDCE2C

Q38621223-575C68A4-004C-4337-9C6F-88442C22860A

Q38621223-96E1BE3A-E100-4DD6-B14B-F80C84CF592E

Q38621223-A4A0FAD9-30FE-4BFE-9F19-DF342892153F

Q38621223-A81D74B0-0EFB-4DF0-ADC5-DCC1E5017223

P2507

Q38621223-96B9487A-5590-4E5C-889B-85FC3D326DBE

P275

Q38621223-079316C6-6496-4F49-B797-EAC42B6241E3

P2860

Q38621223-017D6F30-8B25-49C5-8568-9E808413E4D1

Q38621223-01CBC997-018E-4466-A62C-03E42DD0BA7A

Q38621223-039C3FFF-CBAA-41F0-BB29-E6353790866F

Q38621223-06FE716E-1DA3-40AA-A698-E90CC7D95207

Q38621223-0B1A3C39-BEE1-4FB5-8047-A4EEEBBA47BE

Q38621223-10ADB5A5-00C7-4A8F-88DE-B7AC1A671B79

Q38621223-15039A5B-6851-4EB7-A601-8AC63F514789

Q38621223-1911DAC8-327B-4492-B59B-9118E00EB698

Q38621223-1EC9075D-C037-4592-A661-692D7A1CF297

Q38621223-25DCCD8D-D333-457E-A0FA-BCB9CE760646

P2888

Q38621223-B5E46461-0468-4740-A8FB-EB4BB4B2ABAA

P304

Q38621223-F6B8626C-62E5-4AC4-8C84-D009898D50B1

P31

Q38621223-8ccd69e9-4df5-178a-7bdb-89166b6fa233

Q38621223-B6C680B6-D2AF-46BE-AAB7-2AAF8EA3BCC8

Q38621223-E30A8AEB-8E39-454C-929C-F18002FA4E54

Q38621223-af80a186-4d40-6664-04ae-18fc5a8580b2

P356

Q38621223-9839793B-C022-4D36-ABA2-ECE5D73B815D

P478

Q38621223-0D9957FB-0671-4F13-B6D2-D5E40DE2EB17

P5008

Q38621223-937E1BC1-CB1A-4028-9544-F9408E799D09

P577

Q38621223-3136C82F-56C0-466C-9992-FB60A793C86A

P6179

Q38621223-4D34C019-B8DD-4184-BF16-C15D6776683D

P698

Q38621223-1C29F448-13CE-4871-BE3B-BEEF32F2B3B7

Q38621223-7B4ADE14-C215-4392-9E7E-DF70062EC001

P921

Q38621223-0B8181CA-4D3F-4A3A-BD29-59251387763D

Q38621223-B9824744-21AF-4EED-AE37-31F6CFBA5BE5

Q38621223-DB6905D8-AF5C-48CC-8CF7-A7CC619BA93C

Q38621223-e0dbede0-40c8-a76e-00a4-15f54387bdb0

P932

Q38621223-20883D5B-10E0-498A-8E3E-26DC93298049

P356

S40425-017-0271-0

P1433

Journal for Immunotherapy of Cancer

P1476

Society for Immunotherapy of C ...... reatment of bladder carcinoma.

@en

P2093

Ashish M Kamat

http://www.w3.org/2001/XMLSchema#string

Badrinath R Konety

http://www.w3.org/2001/XMLSchema#string

Cheryl T Lee

http://www.w3.org/2001/XMLSchema#string

Daniel P Petrylak

http://www.w3.org/2001/XMLSchema#string

David Langham

http://www.w3.org/2001/XMLSchema#string

Donald L Lamm

http://www.w3.org/2001/XMLSchema#string

Eila C Skinner

http://www.w3.org/2001/XMLSchema#string

Guru Sonpavde

http://www.w3.org/2001/XMLSchema#string

Joaquim Bellmunt

http://www.w3.org/2001/XMLSchema#string

John A Taylor

http://www.w3.org/2001/XMLSchema#string

P2507

Erratum to: Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma.

P275

Creative Commons Attribution 4.0 International

P2860

Combination of Intravesical Chemotherapy and Bacillus Calmette-Guerin Versus Bacillus Calmette-Guerin Monotherapy in Intermediate- and High-risk Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-analysis

Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancer

Cancer statistics, 2016

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS).

Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Car

Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial.

Risk prediction scores for recurrence and progression of non-muscle invasive bladder cancer: an international validation in primary tumours.

Impact of patient navigation on timely cancer care: the Patient Navigation Research Program

P2888

s40425-017-0271-0

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

systematic review

consensus development conference

review article

P356

10.1186/S40425-017-0271-0

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P5008

ScienceSource

P577

2017-08-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1091167162

http://www.w3.org/2001/XMLSchema#string

P698

28807024

http://www.w3.org/2001/XMLSchema#string

28815048

http://www.w3.org/2001/XMLSchema#string

P921

P932

5557323

http://www.w3.org/2001/XMLSchema#string